Clinicians are moving toward managing mild (Grade 1) cytokine release syndrome on an outpatient basis. The most common and ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
Miv-cel was reported to be well tolerated in the KYSA-8 trial. No high-grade cases of cytokine release syndrome or immune ...
When discussing immune cell therapies, it is almost impossible not to mention cytokine release syndrome (CRS), one of the most well-known adverse effects within immunotherapies. CRS involves the ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window While the use of ...
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has received a ...
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has initiated ...
Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...
Cytokine release syndrome can limit aggressive RRMM treatment strategies. Jeffrey Matous, MD: We’re going to talk about hurdles giving these treatments. First, let’s talk about the timing of CRS ...
The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback